Chronic stress enhances microglia activation and exacerbates death of nigral dopaminergic neurons under conditions of inflammation

Journal of Neuroinflammation

Volumn 11, Issue , 2014, Pages

  De Pablos, Rocío M ^a,b   Herrera, Antonio J ^a,b   Espinosa Oliva, Ana M ^a,b   Sarmiento, Manuel ^a,b,c   Muñoz, Mario F ^a,b   Machado, Alberto ^a,b   Venero, José L ^a,b  

^a UNIVERSITY OF SEVILLE   (Spain)

^b Instituto de Biomedicina de Sevilla   (Spain)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Glucocorticoids; Lipopolysaccharide; Microglia; Parkinson's disease; Stress; Substantia nigra

Indexed keywords

CORTICOSTERONE; CYCLOOXYGENASE 2; GLUCOCORTICOID; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CHRONIC STRESS; CLINICAL FEATURE; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DEGENERATIVE DISEASE; DISEASE PREDISPOSITION; DOPAMINERGIC NERVE CELL; FOOD DEPRIVATION; FORCED SWIM TEST; GENE EXPRESSION; IMMOBILIZATION STRESS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LIPID PEROXIDATION; MALE; MESENCEPHALON; MICROGLIA; NERVE CELL NECROSIS; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; RAT; RISK FACTOR; SOCIAL ISOLATION; SUBSTANTIA NIGRA; WATER DEPRIVATION;

ANIMALS; CELL DEATH; CORTICOSTERONE; CYTOKINES; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; GENE EXPRESSION REGULATION; GLIAL FIBRILLARY ACIDIC PROTEIN; INFLAMMATION; LIPID PEROXIDES; MALE; MICROGLIA; NERVE TISSUE PROTEINS; NITRIC OXIDE SYNTHASE TYPE II; POLYSACCHARIDES; RATS; RATS, WISTAR; STRESS, PSYCHOLOGICAL; SUBSTANTIA NIGRA;

EID: 84895452716     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-11-34     Document Type: Article

References (103)

1. Olanow CW, Shapira AHV, Agid Y. Neuroprotection for Parkinson's disease: prospects and promises. Ann Neurol 2003, 53(Suppl 3):S1-S2.
2. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909. 10.1016/S0896-6273(03)00568-3, 12971891.
3. Di Monte DA, Langston JW. Idiopathic and 1-methyl-4phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinsonism. Neuroglia 1995, 989-997. New York: Oxford University Press, Kettenmann H, Ransom BR.
4. Lesage S, Brice A. Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet 2009, 18(R1):R48-R59. 10.1093/hmg/ddp012, 19297401.
5. Gao HM, Liu B, Zhang W, Hong JS. Synergistic dopaminergic neurotoxicity of MPTP and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease. FASEB J 2003, 17:1957-1959.
6. Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurol 2009, 8:382-397. 10.1016/S1474-4422(09)70062-6, 19296921.
7. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 2003, 53(Suppl 3):S26-S38.
8. Marchetti B, Abbracchio MP. To be or not to be (inflamed): Is that the question in anti-inflammatory drug therapy of neurodegenerative disorders?. Trends Pharmacol Sci 2005, 26:517-525. 10.1016/j.tips.2005.08.007, 16126283.
9. Marchetti B, Serra PA, L'Episcopo F, Tirolo C, Caniglia S, Testa N, Cioni S, Gennuso F, Rocchitta G, Desole MS, Mazzarino MC, Miele E, Morale MC. Hormones are key actors in gene × environment interactions programming vulnerability to Parkinson's disease: glia as a common final pathway. Ann N Y Acad Sci 2005, 1057:296-318. 10.1196/annals.1356.023, 16399902.
10. Marchetti B, Serra PA, Tirolo C, 'L'Episcopo F, Caniglia S, Gennuso F, Testa N, Miele E, Desole S, Barden N, Morale MC. Glucocorticoid receptor-nitric oxide crosstalk and vulnerability to experimental Parkinsonism: pivotal role for glia-neuron interactions. Brain Res Rev 2005, 48:302-321. 10.1016/j.brainresrev.2004.12.030, 15850669.
11. McGeer PL, McGeer EG. Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord 2004, 10(Suppl 1):S3-S7.
12. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988, 38:1285-1291. 10.1212/WNL.38.8.1285, 3399080.
13. Klegeris A, McGeer EG, McGeer PL. Therapeutic approaches to inflammation in neurodegenerative disease. Curr Opin Neurol 2007, 20:351-357. 10.1097/WCO.0b013e3280adc943, 17495632.
14. McGeer PL, McGeer EG. Glial reactions in Parkinson's disease. Mov Disord 2008, 23:474-483. 10.1002/mds.21751, 18044695.
15. Tansey MG, McCoy MK, Frank-Cannon TC. Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol 2007, 208:1-25. 10.1016/j.expneurol.2007.07.004, 3707134, 17720159.
16. Cicchetti F, Brownell AL, Williams K, Chen YI, Livni E, Isacson O. Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur J Neurosci 2002, 15:991-998. 10.1046/j.1460-9568.2002.01938.x, 11918659.
17. Gao HM, Jiang J, Wilson B, Zhang W, Hong JS, Liu B. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J Neurochem 2002, 81:1285-1297. 10.1046/j.1471-4159.2002.00928.x, 12068076.
18. Liberatore GT, Jackson-Lewis V, Vukosavic S, Mandir AS, Vila M, McAuliffe WG, Dawson VL, Dawson TM, Przedborski S. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 1999, 5:1403-1409. 10.1038/70978, 10581083.
19. Miklossy J, Doudet DD, Schwab C, Yu S, McGeer EG, McGeer PL. Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys. Exp Neurol 2006, 197:275-283. 10.1016/j.expneurol.2005.10.034, 16336966.
20. Holst O, Ulmer AJ, Brade H, Flad HD, Rietschel ET. Biochemistry and cell biology of bacterial endotoxins. FEMS Immunol Med Microbiol 1996, 16:83-104. 10.1111/j.1574-695X.1996.tb00126.x, 8988390.
21. Kielian TL, Blecha F. CD14 and other recognition molecules for lipopolysaccharide: a review. Immunopharmacology 1995, 29:187-205. 10.1016/0162-3109(95)00003-C, 7542643.
22. Godoy M, Tarelli R, Ferrari CC, Sarchi MI, Pitossi FJ. Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease. Brain 2008, 131:1880-1894. 10.1093/brain/awn101, 2442423, 18504291.
23. Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, Ascherio A. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol 2005, 58:963-967. 10.1002/ana.20682, 16240369.
24. Chen H, Zhang S, Hernán MA, Schwarzschild MA, Willett WC, Colditz GA, Speizer FE, Ascherio A. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 2003, 60:1059-1064. 10.1001/archneur.60.8.1059, 12925360.
25. Esposito E, Di Matteo V, Benigno A, Pierucci M, Crescimanno G, Di Giovanni G. Non-steroidal anti-inflammatory drugs in Parkinson's disease. Exp Neurol 2007, 205:295-312. 10.1016/j.expneurol.2007.02.008, 17433296.
26. Castaño A, Herrera AJ, Cano J, Machado A. Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J Neurochem 1998, 70:1584-1592.
27. Castaño A, Herrera AJ, Cano J, Machado A. The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh-TNF-α, IL-1β and IFN-γ. J Neurochem 2002, 81:150-157. 10.1046/j.1471-4159.2002.00799.x, 12067227.
28. Herrera AJ, Castaño A, Venero JL, Cano J, Machado A. The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system. Neurobiol Dis 2000, 7:429-447. 10.1006/nbdi.2000.0289, 10964613.
29. Kim WG, Mohney RP, Wilson B, Jeohn GH, Liu B, Hong JS. Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J Neurosci 2000, 20:6309-6316.
30. Gayle DA, Ling Z, Tong C, Landers T, Lipton JW, Carvey PM. Lipopolysaccharide (LPS)-induced dopamine cell loss in culture: roles of tumor necrosis factor-α, interleukin-1β, and nitric oxide. Brain Res Dev Brain Res 2002, 133:27-35. 10.1016/S0165-3806(01)00315-7, 11850061.
31. Jeohn GH, Cooper CL, Wilson B, Chang RC, Jang KJ, Kim HC, Liu B, Hong JS. p38 MAP kinase is involved in lipopolysaccharide-induced dopaminergic neuronal cell death in rat mesencephalic neuron-glia cultures. Ann N Y Acad Sci 2002, 962:332-346. 10.1111/j.1749-6632.2002.tb04078.x, 12076985.
32. Liu B, Du L, Hong JS. Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation. J Pharmacol Exp Ther 2000, 293:607-617.
33. Liu Y, Qin L, Li G, Zhang W, An L, Liu B, Hong JS. Dextromethorphan protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation. J Pharmacol Exp Ther 2003, 305:212-218. 10.1124/jpet.102.043166, 12649371.
34. Foley P, Gerlach M, Double KL, Riederer P. Dopamine receptor agonists in the therapy of Parkinson's disease. J Neural Transm 2004, 111:1375-1446. 10.1007/s00702-003-0059-x, 15480844.
35. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, McClay J, Mill J, Martin J, Braithwaite A, Poulton R. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003, 301:386-389. 10.1126/science.1083968, 12869766.
36. Kendler KS, Karkowski-Shuman L. Stressful life events and genetic liability to major depression: genetic control of exposure to the environment?. Psychol Med 1997, 27:539-547. 10.1017/S0033291797004716, 9153675.
37. Charcot JM. Lectures on the Diseases of the Nervous System, Volume 1 1878, London: The New Sydenham Society, (English translation by Sigerson G).
38. Gowers WR. Diseases of the Nervous System 1888, Philadelphia, PA: Blakiston, Son & Co, (American edition).
39. McEwen BS. Protective and damaging effects of stress mediators: the good and bad sides of the response to stress. Metabolism 2002, 51(6 Suppl 1):2-4.
40. McEwen BS. The neurobiology of stress: from serendipity to clinical relevance. Brain Res 2000, 886:172-189. 10.1016/S0006-8993(00)02950-4, 11119695.
41. de Kloet ER, Joles M, Holsboer F. Stress and the brain: from adaptation to disease. Nat Rev Neurosci 2005, 6:463-475. 10.1038/nrn1683, 15891777.
42. Joëls M, Krugers H, Karst H. Stress-induced changes in hippocampal function. Prog Brain Res 2008, 167:3-15.
43. Espinosa-Oliva AM, de Pablos RM, Villarán RF, Arguelles S, Venero JL, Machado A, Cano J. Stress is critical for LPS-induced activation of microglia and damage in the rat hippocampus. Neurobiol Aging 2011, 32:85-102. 10.1016/j.neurobiolaging.2009.01.012, 19286276.
44. de Pablos RM, Villaran RF, Argüelles S, Herrera AJ, Venero JL, Ayala A, Cano J, Machado A. Stress increases vulnerability to inflammation in the rat prefrontal cortex. J Neurosci 2006, 26:5709-5719. 10.1523/JNEUROSCI.0802-06.2006, 16723527.
45. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates 1986, London: Academic Press.
46. Gamaro GD, Manoli P, Torres IL, Silveira R, Dalmaz C. Effects of chronic variate stress on feeding behavior and on monoamine levels in different rat brain structures. Neurochem Int 2003, 42:107-114. 10.1016/S0197-0186(02)00080-3, 12421590.
47. Konarska M, Stewart RE, McCarty R. Predictability of chronic intermittent stress: effects on sympathetic-adrenal medullary responses of laboratory rats. Behav Neural Biol 1990, 53:231-243. 10.1016/0163-1047(90)90458-I, 2331234.
48. Murua VS, Molina VA. Effects of chronic variable stress and antidepressant drugs on behavioral inactivity during an uncontrollable stress: interaction between both treatments. Behav Neural Biol 1992, 57:87-89. 10.1016/0163-1047(92)90790-B, 1567336.
49. Muscat R, Papp M, Willner P. Reversal of stress-induced anhedonia by the atypical antidepressants, fluoxetine and maprotiline. Psychopharmacology (Berl) 1992, 109:433-438. 10.1007/BF02247719, 1365858.
50. Papp M, Willner P, Muscat R. An animal model of anhedonia: attenuation of sucrose consumption and place preference conditioning by chronic unpredictable mild stress. Psychopharmacology (Berl) 1991, 104:255-259. 10.1007/BF02244188, 1876670.
51. Willner P, Towell A, Sampson D, Sophokleous S, Muscat R. Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology (Berl) 1987, 93:358-364.
52. Gundersen HGJ, Bagger P, Bendtsen TF, Evans SM, Korbo L, Marcussen N, Møller A, Nielsen K, Nyengaard JR, Pakkenberg B, Sørensen FB, Vesterby A, West MJ. The new stereological tools: disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis. APMIS 1988, 96:857-881. 10.1111/j.1699-0463.1988.tb00954.x, 3056461.
53. Meltzer JC, Sanders V, Grimm PC, Stern E, Rivier C, Lee S, Rennie SL, Gietz RD, Hole AK, Watson PH, Greenberg AH, Nance DM. Production of digoxigenin-labelled RNA probes and the detection of cytokine mRNA in rat spleen and brain by in situ hybridization. Brain Res Brain Res Protoc 1998, 2:339-351. 10.1016/S1385-299X(98)00010-5, 9630715.
54. Lee DY, Oh YJ, Jin BK. Thrombin-activated microglia contributes to death of dopaminergic neurons in rat mesencephalic cultures: dual roles of mitogen-activated protein kinase signaling pathways. Glia 2005, 51:98-110. 10.1002/glia.20190, 15789435.
55. Rostworowski M, Balasingam V, Chabot S, Owens T, Yong VW. Astrogliosis in the neonatal and adult murine brain post-trauma: elevation of inflammatory cytokines and the lack of requirement for endogenous interferon-γ. J Neurosci 1997, 17:3664-3674.
56. Kim YW, Zhao RJ, Park SJ, Lee JR, Cho IJ, Yang CH, Kim SG, Kim SC. Anti-inflammatory effects of liquiritigenin as a consequence of the inhibition of NF-κB-dependent iNOS and pro-inflammatory cytokines production. Br J Pharmacol 2008, 154:165-173. 10.1038/bjp.2008.79, 2438972, 18332856.
57. Bland ST, Beckley JT, Watkins LR, Maier SF, Bilbo SD. Neonatal Escherichia coli infection alters glial, cytokine, and neuronal gene expression in response to acute amphetamine in adolescent rats. Neurosci Lett 2010, 474:52-57. 10.1016/j.neulet.2010.03.006, 2865898, 20223277.
58. Zhu J, Zhou Z, Liu Y, Zheng J. Fractalkine and CX3CR1 are involved in the migration of intravenously grafted human bone marrow stromal cells toward ischemic brain lesion in rats. Brain Res 2009, 1287:173-183.
59. Fryer HJ, Davis GE, Manthorpe M, Varon S. Lowry protein assay using an automatic microtiter plate spectrophotometer. Anal Biochem 1986, 153:262-266. 10.1016/0003-2697(86)90090-4, 3706709.
60. Jiang ZY, Woollard AC, Wolff SP. Lipid hydroperoxide measurement by oxidation of Fe2+ in the presence of xylenol orange: comparison with the TBA assay and an iodometric method. Lipids 1991, 26:853-856. 10.1007/BF02536169, 1795606.
61. Tomás-Camardiel M, Venero JL, Herrera AJ, de Pablos RM, Pintor-Toro JA, Machado A, Cano J. Blood-brain barrier disruption highly induces aquaporin-4 mRNA and protein in perivascular and parenchymal astrocytes: protective effect by estradiol treatment in ovariectomized animals. J Neurosci Res 2005, 80:235-246. 10.1002/jnr.20443, 15772982.
62. Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res 2009, 29:313-326. 10.1089/jir.2008.0027, 2755091,2755091, 19441883.
63. Hickman SE, El Khoury J. Mechanisms of mononuclear phagocyte recruitment in Alzheimer's disease. CNS Neurol Disord Drug Targets 2010, 9:168-173. 10.2174/187152710791011982, 3684802, 20205643.
64. Morimoto M, Morita N, Ozawa H, Yokoyama K, Kawata M. Distribution of glucocorticoid receptor immunoreactivity and mRNA in the rat brain: an immunohistochemical and in situ hybridization study. Neurosci Res 1996, 26:235-269. 10.1016/S0168-0102(96)01105-4, 9121734.
65. Venero JL, Burguillos MA, Brundin P, Joseph B. The executioners sing a new song: killer caspases activate microglia. Cell Death Differ 2011, 18:1679-1691. 10.1038/cdd.2011.107, 3190105, 21836616.
66. Lawson LJ, Perry VH, Dri P, Gordon S. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 1990, 39:151-170. 10.1016/0306-4522(90)90229-W, 2089275.
67. Smith LK, Jadavji NM, Colwell KL, Katrina Perehudoff S, Metz GA. Stress accelerates neural degeneration and exaggerates motor symptoms in a rat model of Parkinson's disease. Eur J Neurosci 2008, 27:2133-2146. 10.1111/j.1460-9568.2008.06177.x, 18412632.
68. Burguillos MA, Deierborg T, Kavanagh E, Persson A, Hajji N, Garcia-Quintanilla A, Cano J, Brundin P, Englund E, Venero JL, Joseph B. Caspase signalling controls microglia activation and neurotoxicity. Nature 2011, 472:319-324. 10.1038/nature09788, 21389984.
69. Frank MG, Miguel ZD, Watkins L, Maier SF. Prior exposure to glucocorticoids sensitizes the neuroinflammatory and peripheral inflammatory responses to E. coli lipopolysaccharide. Brain Behav Immun 2010, 24:19-30. 10.1016/j.bbi.2009.07.008, 19647070.
70. Frank MG, Thompson BM, Watkins LR, Maier SF. Glucocorticoids mediate stress-induced priming of microglial pro-inflammatory responses. Brain Behav Immun 2012, 26:337-345. 10.1016/j.bbi.2011.10.005, 22041296.
71. Frank MG, Watkins LR, Maier SF. Stress- and glucocorticoid-induced priming of neuroinflammatory responses: potential mechanisms of stress-induced vulnerability to drugs of abuse. Brain Behav Immun 2011, 25(Suppl 1):S21-S28.
72. Johnson JD, O'Connor KA, Deak T, Stark M, Watkins LR, Maier SF. Prior stressor exposure sensitizes LPS-induced cytokine production. Brain Behav Immun 2002, 16:461-476. 10.1006/brbi.2001.0638, 12096891.
73. Perry VH. The influence of systemic inflammation on inflammation in the brain: implications for chronic neurodegenerative disease. Brain Behav Immun 2004, 18:407-413. 10.1016/j.bbi.2004.01.004, 15265532.
74. Smyth GP, Stapleton PP, Freeman TA, Concannon EM, Mestre JR, Duff M, Maddali S, Daly JM. Glucocorticoid pretreatment induces cytokine overexpression and nuclear factor-κB activation in macrophages. J Surg Res 2004, 116:253-261. 10.1016/S0022-4804(03)00300-7, 15013364.
75. Sorrells SF, Sapolsky RM. An inflammatory review of glucocorticoid actions in the CNS. Brain Behav Immun 2007, 21:259-272. 10.1016/j.bbi.2006.11.006, 1997278, 17194565.
76. Kierdorf K, Prinz M. Factors regulating microglia activation. Front Cell Neurosci 2013, 7:44. 3632747, 23630462.
77. Conductier G, Blondeau N, Guyon A, Nahon JL, Rovère C. The role of monocyte chemoattractant protein MCP1/CCL2 in neuroinflammatory diseases. J Neuroimmunol 2010, 224:93-100. 10.1016/j.jneuroim.2010.05.010, 20681057.
78. Barclay AN, Wright GJ, Brooke G, Brown MH. CD200 and membrane protein interactions in the control of myeloid cells. Trends Immunol 2002, 23:285-290. 10.1016/S1471-4906(02)02223-8, 12072366.
79. Hoek RM, Ruuls SR, Murphy CA, Wright GJ, Goddard R, Zurawski SM, Blom B, Homola ME, Streit WJ, Brown MH, Barclay AN, Sedgwick JD. Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science 2000, 290:1768-1771.
80. Biber K, Neumann H, Inoue K, Boddeke HW. Neuronal 'On' and 'Off' signals control microglia. Trends Neurosci 2007, 30:596-602. 10.1016/j.tins.2007.08.007, 17950926.
81. Cardona AE, Pioro EP, Sasse ME, Kostenko V, Cardona SM, Dijkstra IM, Huang D, Kidd G, Dombrowski S, Dutta R, Lee JC, Cook DN, Jung S, Lira SA, Littman DR, Ransohoff RM. Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci 2006, 9:917-924. 10.1038/nn1715, 16732273.
82. Sozzani S, Zhou D, Locati M, Rieppi M, Proost P, Magazin M, Vita N, van Damme J, Mantovani A. Receptors and transduction pathways for monocyte chemotactic protein-2 and monocyte chemotactic protein-3: Similarities and differences with MCP-1. J Immunol 1994, 152:3615-3622.
83. Stamatovic SM, Keep RF, Kunkel SL, Andjelkovic AV. Potential role of MCP-1 in endothelial cell tight junction 'opening': signaling via Rho and Rho kinase. J Cell Sci 2003, 116:4615-4628. 10.1242/jcs.00755, 14576355.
84. Ataka K, Asakawa A, Nagaishi K, Kaimoto K, Sawada A, Hayakawa Y, Tatezawa R, Inui A, Fujimiya M. Bone marrow-derived microglia infiltrate into the paraventricular nucleus of chronic psychological stress-loaded mice. PLoS One 2013, 8:e81744. 10.1371/journal.pone.0081744, 3841189, 24303068.
85. Calvez J, Fromentin G, Nadkarni N, Darcel N, Even P, Tomé D, Ballet N, Chaumontet C. Inhibition of food intake induced by acute stress in rats is due to satiation effects. Physiol Behav 2011, 104:675-683. 10.1016/j.physbeh.2011.07.012, 21787797.
86. Nair A, Bonneau RH. Stress-induced elevation of glucocorticoids increases microglia proliferation through NMDA receptor activation. J Neuroimmunol 2006, 171:72-85. 10.1016/j.jneuroim.2005.09.012, 16278020.
87. Ros-Bernal F, Hunot S, Herrero MT, Parnadeau S, Corvol JC, Lu L, Alvarez-Fischer D, Carrillo-de Sauvage MA, Saurini F, Coussieu C, Kinugawa K, Prigent A, Höglinger G, Hamon M, Tronche F, Hirsch EC, Vyas S. Microglial glucocorticoid receptors play a pivotal role in regulating dopaminergic neurodegeneration in parkinsonism. Proc Natl Acad Sci USA 2011, 108:6632-6637. 10.1073/pnas.1017820108, 3080980, 21467220.
88. Kim YM, Lee JY, Choi SH, Kim DG, Jahng JW. RU486 blocks fasting-induced decrease of neuronal nitric oxide synthase in the rat paraventricular nucleus. Brain Res 2004, 1018:221-226. 10.1016/j.brainres.2004.05.068, 15276881.
89. Mailliet F, Qi H, Rocher C, Spedding M, Svenningsson P, Jay TM. Protection of stress-induced impairment of hippocampal/prefrontal LTP through blockade of glucocorticoid receptors: implication of MEK signaling. Exp Neurol 2008, 211:593-596. 10.1016/j.expneurol.2008.02.030, 18436212.
90. Sharrett-Field L, Butler TR, Berry JN, Reynolds AR, Prendergast MA. Mifepristone pretreatment reduces ethanol withdrawal severity in vivo. Alcohol Clin Exp Res 2013, 37:1417-1423. 10.1111/acer.12093, 23527822.
91. Ahima RS, Harlan RE. Charting of type II glucocorticoid receptor-like immunoreactivity in the rat central nervous system. Neuroscience 1990, 39:579-604. 10.1016/0306-4522(90)90244-X, 1711170.
92. Ahima RS, Tagoe CNB, Harlan RE. Type II corticosteroid receptor-like immunoreactivity in the rat cerebellar cortex: differential regulation by corticosterone. Neuroendocrinology 1992, 55:683-694. 10.1159/000126188, 1630584.
93. Maki BE, McIlroy WE. Influence of arousal and attention on the control of postural sway. J Vestib Res 1996, 6:53-59.
94. Metz GA, Jadavji NM, Smith LK. Modulation of motor function by stress: a novel concept of the effects of stress on behavior. Eur J Neurosci 2005, 22:1190-1200. 10.1111/j.1460-9568.2005.04285.x, 16176362.
95. Metz GAS, Schwab ME, Welzl H. The effects of acute and chronic stress on motor and sensory performance in male Lewis rats. Physiol Behav 2001, 72:29-35. 10.1016/S0031-9384(00)00371-1, 11239978.
96. Charlett A, Dobbs RJ, Purkiss AG, Wright DJ, Peterson DW, Weller C, Dobbs SM. Cortisol is higher in parkinsonism and associated with gait deficit. Acta Neurol Scand 1998, 97:77-85.
97. Kim ST, Choi JH, Chang JW, Kim SW, Hwang O. Immobilization stress causes increases in tetrahydrobiopterin, dopamine, and neuromelanin and oxidative damage in the nigrostriatal system. J Neurochem 2005, 95:89-98. 10.1111/j.1471-4159.2005.03342.x, 16181415.
98. Finlay JM, Zigmond MJ. The effects of stress on central dopaminergic neurons: possible clinical implications. Neurochem Res 1997, 22:1387-1394. 10.1023/A:1022075324164, 9355111.
99. Izzo E, Sanna PP, Koob GF. Impairment of dopaminergic system function after chronic treatment with corticotropin-releasing factor. Pharmacol Biochem Behav 2005, 81:701-708. 10.1016/j.pbb.2005.04.017, 16005056.
100. Pani L, Porcella A, Gessa GL. The role of stress in the pathophysiology of the dopaminergic system. Mol Psychiatry 2000, 5:14-21. 10.1038/sj.mp.4000589, 10673764.
101. Smith AD, Castro SL, Zigmond MJ. Stress-induced Parkinson's disease: a working hypothesis. Physiol Behav 2002, 77:527-531. 10.1016/S0031-9384(02)00939-3, 12526994.
102. Zigmond MJ, Abercrombie ED, Berger TW, Grace AA, Stricker EM. Compensatory responses to partial loss of dopaminergic neurons: studies with 6-hydroxydopamine. Current Concepts in Parkinson's Disease Research 1993, 99-140. Toronto: Hogrefe & Huber, Schneider JS, Gupta M.
103. Stein-Behrens BA, Elliot EM, Miller CA, Schilling JW, Newcombe R, Sapolsky RM. Glucocorticoids exacerbate kainic acid-induced extracellular accumulation of excitatory amino acids in the rat hippocampus. J Neurochem 1992, 58:1730-1735. 10.1111/j.1471-4159.1992.tb10047.x, 1560229.